MAP2K7 and neurofibromatosis type 1: In 2021, the FDA approved the MEK inhibitor selumetinib for pediatric patients with neurofibromatosis type 1, a genetic disorder in which NF1 loss predisposes to peripheral nerve sheath tumors and other cancers (Table 1) [95,96].